Overall survival: Median length of · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Febrile neutropenia · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Diarrhoea · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Bone metastases · women with early breast cancer
Bisphosphonates probably leads to lower bone metastases compared with placebo/observation (moderate certainty).
1 finding from 1 review
Infusion‐related events · women with early breast cancer
1 finding from 1 review
Overall survival · women with early breast cancer
Bisphosphonates leads to lower overall survival compared with placebo/observation (high certainty).
1 finding from 1 review
Overall survival postmenopausal women · women with early breast cancer
Bisphosphonates leads to lower overall survival postmenopausal women compared with placebo/observation (high certainty).
1 finding from 1 review
Overall survival: pre‐ or perimenopausal women · women with early breast cancer
Bisphosphonates showed no clear difference in overall survival: pre‐ or perimenopausal women compared with placebo/observation (high certainty).
1 finding from 1 review
Disease‐free progression · women with early breast cancer
Bisphosphonates showed no clear difference in disease‐free progression compared with placebo/observation (high certainty).
1 finding from 1 review
Disease‐free progression: postmenopausal women · women with early breast cancer
Bisphosphonates leads to lower disease‐free progression: postmenopausal women compared with placebo/observation (high certainty).
1 finding from 1 review
Disease‐free progression: pre‐ or perimenopausal women · women with early breast cancer
Bisphosphonates showed no clear difference in disease‐free progression: pre‐ or perimenopausal women compared with placebo/observation (high certainty).
1 finding from 1 review
Incidence of fractures · women with early breast cancer
Bisphosphonates showed no clear difference in fracture incidence compared with placebo/observation (moderate certainty).
1 finding from 1 review
Adverse events: osteonecrosis of the jaw · women with early breast cancer
1 finding from 1 review
Intervention not reported
Breast cancer stage at the time of presentation: defined as the proportion of women with breast cancer diagnosed at late stage (stage III, IV) Time of outcome assessment: 3 years to 20 years Method of measurement: CBE · health workers
The intervention may leads to lower breast cancer stage at the time of presentation: defined as the… (low certainty).
1 finding from 1 review
Intervention not reported
Accuracy of health worker‐performed CBE Time of outcome assessment: 2 years to 20 years Method of measurement: Sensitivity, specificity and positive predictive value · health workers
1 finding from 1 review
Intervention not reported
CBE coverage Time of outcome assessment: 20 years Method of measurement: active surveillance · health workers
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
Intervention not reported
Completion of · health workers
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
Intervention not reported
Breast cancer mortality: defined as deaths among women who received a diagnosis of breast cancer Time of outcome assessment: 3 years to 20 years Method of measurement: death registration offices, hospital records, and house visits · health workers
It is very uncertain whether the intervention changes breast cancer mortality: defined as deaths among women who received… (very low certainty).
1 finding from 1 review
Locoregional recurrence · women with breast cancer and one to three positive lymph nodes
Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) may leads to lower local and regional recurrence (LRR) compared with no PMRT (low certainty).
1 finding from 1 review